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ABSTRACT
Alzheimer´s disease (AD) is characterized by progressive dementia, initially 
presenting olfactory dysfunction. Despite the olfactory bulb (OB) is the first central 
structure of the olfactory pathway, we lack a complete molecular characterization of 
the transcriptional events that occurs in this olfactory area during AD progression. 
To address this gap in knowledge, we have assessed the genome-wide expression 
in postmortem OBs from subjects with varying degree of AD pathology. A stage-
dependent deregulation of specific pathways was observed, revealing transmembrane 
transport, and neuroinflammation as part of the functional modules that are disrupted 
across AD grading. Potential drivers of neurodegeneration predicted by network-
driven transcriptomics were monitored across different types of dementia, including 
progressive supranuclear palsy (PSP), mixed dementia, and frontotemporal lobar 
degeneration (FTLD). Epidermal growth factor receptor (EGFR) expression was 
significantly increased in the OB of AD and mixed dementia subjects. Moreover, 
a significant increment in the activation of signal transducer and activator of 
transcription 3 (STAT3) was exclusively detected in advanced AD stages, whereas 
total STAT3 levels were specifically overexpressed in mixed dementia. Furthermore, 
transcription factors deregulated in the OB of mixed dementia subjects such as cAMP 
Responsive Element Binding Protein 1 (CREB1) and AP-1 Transcription Factor Subunit 
(c-Jun) were not differentially modulated at olfactory level across AD grading. On the 
other hand, olfactory expression of this signal transducer panel was unchanged in 
PSP and FTLD subjects. Taken together, this study unveils cross-disease similarities 
and differences for specific signal transducers, providing mechanistic clues to the 
intriguing divergence of AD pathology across proteinopathies.
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INTRODUCTION
Although olfactory involvement may also appear 
in healthy non-demented elderly subjects [1], olfactory 
dysfunction is present in up to 90% of AD patients [2]. 
Some studies suggest that olfactory dysfunction is an 
early event of AD, preceding the appearance of typical 
AD symptoms, such as memory loss, and dementia. The 
olfactory bulb (OB) is the first central structure of the 
olfactory pathway in the brain [3]. An OB atrophy and a 
significant reduction in olfactory performance have been 
detected in AD respect to control subjects using MRI and 
PET technologies [4, 5]. From a neuropathological point 
of view, olfactory centres are involved in early Braak 
stages [6], and OB pathology correlates with cortical 
AD pathology [7–9]. In view of these data, an in depth 
biochemical characterization of the neurodegeneration 
that occurs in the OB is mandatory as a first step for 
understanding early smell impairment in AD. Although 
neuroanatomical, volumetric, and histological approaches 
have been the gold standard techniques employed to 
characterize the OB functionality, little attention has 
been focused specifically on the molecular composition 
of the OB from the perspective of high throughput 
molecular technologies [10, 11]. Different transcriptomic 
studies have been attempted to discover novel regulatory 
mechanisms associated with AD pathogenesis in 
brain areas differentially affected by the disease [12]. 
Nevertheless, no study to date has addressed whether 
specific patterns of gene expression is associated to 
the development of human AD-related pathology at 
olfactory level in a stage-dependent manner. We consider 
that deciphering the progressive transcriptome-wide 
alterations that occurs in the OB derived from human 
AD cases with different Braak staging, might help 
develop early diagnosis and identify potential therapeutic 
targets for AD. In this study, we have analyzed the 
progressive modulation of the OB transcriptome across 
neuropathological stages of AD, in order to increase our 
knowledge about the pathophysiological mechanisms 
that are disturbed during the AD neurodegeneration in 
the OB. 249 differential genes were detected between 
controls and AD-related phenotypes, pinpointing specific 
pathways, gene interaction networks, and potential novel 
therapeutic targets that are modulated in specific AD 
stages. Interestingly, the OB transcriptome exploration in 
parallel with a cross-disease analysis including different 
proteinopathies, has revealed distinct modulation of 
specific signal transducers, providing new avenues 
of research into the role of olfactory signaling across 
different types of dementias.
RESULTS AND DISCUSSION
During the last decade, gene expression profiling of 
postmortem tissue has greatly increased our knowledge 
about the pathophysiological mechanisms that occur in 
affected brain structures during AD progression [12]. 
With the aim to identify downstream aberrant gene 
expression related to beta-amyloid and Tau deposits 
across AD phenotypes, the temporal lobe–hippocampus 
and the frontal–prefrontal cortex has been the most 
studied areas [12–16]. However, loss of smell is involved 
in early stages of AD, partially due to an imbalance in 
the OB functionality [17]. Albeit olfactory impairment 
is considered an important clinical marker and predictor 
of AD progression [18], the mechanisms governing this 
dysfunction are still poorly understood. Transcriptome 
profiling has revealed multiple metabolic alterations in the 
OB of a rat AD model [19], however, the progression of 
the disease in rodent models does not correlate well with 
human AD [20], being necessary genome-wide studies 
in human olfactory tissue with neuropathologically well-
defined AD-associated changes (Figure 1).
OB transcriptome dynamics during AD 
progression
The immunohistochemical study of β-amyloid 
and phospho-Tau protein in the cases included in this 
study (Table 1), allowed us to confirm the presence 
of neuropathological proteins in the OB of subjects 
with distinct stages of AD (Figure 2), confirming the 
involvement of OB in pre-clinical stages of the disease. 
To further understand the olfactory molecular background 
contributing to the progression of AD, we have performed 
a differential OB transcriptome analysis in order to 
detect early and stage-dependent molecular events 
underlying the progression of the disease at olfactory 
level (Figure 1). As shown in Figure 3, 103, 78, and 
105 differentially expressed protein-coding genes were 
detected in initial, intermediate, and advanced AD stages 
respectively (Supplementary Table 2). In our sample 
set, the distribution between up-regulated and down-
regulated protein coding-genes was very similar across 
AD grading (Figure 3A). As expected, we detected a 
substantial heterogeneity within the same Braak staging. 
This may be due to unpredictable confounders such as 
clinical, environmental, behavioral and agonal factors 
(i.e medication, substance abuse and health status prior 
to death) [21]. However, 10 genes were modulated across 
all stages (Figure 3B), suggesting a potential role during 
AD progression (Table 2), although we can not discard 
that this subset of olfactory genes may be also primary 
related to the neurodegenerative process that occur in 
other neurodegenerative diseases with common smell 
impairment. Some of these genes are involved in synaptic 
plasticity (EGFLAM), zinc transporter (SLC39A11), 
retinoid carrier (LCN10), and sodium and carbohydrate 
transport (SLC5A11). Other differential expressed 
genes overlapped between initial-intermediate stages, 
intermediate-advanced stages, and initial-advanced stages 
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(Table 2). We have investigated whether the differential 
OB transcriptomic fingerprint has been partially reflected 
in previous transcriptomic studies performed in different 
brain structures across AD pathology [15, 22–27]. 
According to our integrative meta-analysis (Supplementary 
Table 3), most of the differential OB genes have not been 
previously proposed as differential molecular features in 
hippocampal structures affected by the disease, serving as 
a foundation for new areas of investigation into the role 
of olfactory signaling in human AD. However, due to 
the OB pathology correlates with cortical AD pathology 
[7–9], we compared our differential gene sets with the 
differential expressed genome that previously showed 
significant expression correlation to Braak stage and 
cerebral atrophy in prefrontal cortex from AD subjects 
[16]. Thirteen OB differential genes in initial stages 
(KLC1, RAB7L1, C8orf46, GRM8, DCC, TMEM9, 
DDA1, HPCAL1, C15orf37, SYT13, VIP, RGS4, SST), 
seven differential expressed OB genes in intermediate 
stages (OR2T2, LOR, DCLRE1C, HMOX2, UBE2NL, 
SYT13), and eight differential OB genes in advanced 
stages (ZNF443, PHF17, CEP68, UIMC1, SMAD5, 
ELF1, PTPN2, CASP1) present a significant expression 
correlation to Braak staging at cortical level [16]. 
Moreover, twenty OB early-deregulated genes (C15orf37, 
C8orf46, DCC, DDA1, GIMAP7, GRM8, HPCAL1, KLC1, 
PDE10A, RASAL1, RGS4, SST,TMEM204, TMEM9, VIP, 
TMSB15B, RAB7L1, SYT13, EGFLAM, SLC39A11), 
sixteen OB intermediate-affected genes (TMSB15B, 
RAB7L1, SYT13, ESAM, EGFLAM, SLC39A11, CTXN3, 
DCLRE1C, GTF3C6, HLA-DRA, HMOX2, LOR, 
NBPF1, OR2T2, RASL11B, SNRPN), and fifteen OB 
advanced-deregulated genes (EGFLAM, SLC39A11, 
ESAM, CASP1, CD58, CEP68, CHRM4, ELF1, PHF17, 
PTPN2, SERPINH1, SMAD5, TUBA1A, UIMC1, ZNF443) 
showed a good correlation with cerebral atrophy [16]. 
Figure 1: An overview of the workflow used for the characterization of OB transcriptome during AD evolution.
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Although our stage-dependent analysis presents a limited 
number of study population, these data shed new light 
on the potential coordinated regulation of specific gene 
modules across AD-related brain structures, reinforcing 
the molecular correlation between OB and cortical AD 
pathology beyond the presence and distribution of beta-
amyloid and phospho-Tau protein [7–9]. Using data 
mining-based methods for proteome-scale protein-protein 
interaction predictions [28], we have generated the 
potential interactome for human APP (β-amyloid precursor 
protein) and Tau protein (Supplementary Table 4), 
detecting some OB differentially expressed protein-
coding genes as potential APP and/or Tau interactors. 
Specifically, differentially expressed genes in initial stages 
like RASAL1, TUBB4A, and BTK genes are potential APP 
interactors, whereas MAPK8IP1, and HSPA1B genes 
(deregulated in advanced stages) may be potential Tau 
interactors. Although these predictive assumptions should 
be experimentally validated, this information may be 
useful to generate new working hypothesis to clarify the 
relationship between both neuropathologic substrates 
in AD at olfactory level. KLC1 gene (Kinesin 2) is a 
common interactor between both neuropathological 
substrates (Supplementary Table 4). Moreover, RASAL1, 
TUBB4A, and KLC1 are also deregulated in cortical areas 
from AD patients [24, 27], being KLC1 a modifier of the 
beta-amyloid accumulation [29]. Interestingly, kinesin 2 
protein levels were significantly increased in the OB from 
initial and advanced AD stages (Supplementary Figure 1). 
In addition, HSPA1B gene (up-regulated in advanced AD 
at the level of OB) is also up-regulated at protein level 
in hippocampus from AD subjects [30]. RASAL1 and 
TUBB4A genes (up-regulated in initial AD at the level of 
OB) are down-regulated in hippocampal proteome at all 
pathologic stages of AD [30]. All these evidences suggest 
that AD pathology modulates the gene/protein expression 
Table 1: Summary of selected cases included in this study
Duration PMI Pathological diagnosis IHQ: βA in OB IHQ: TAU in OB
Cases age sex (years) (hours) NIA-AA criteria MP DP Tangles neurites
Control
C1 72 M 9 Thal 1 Cerad 1 no tau deposit − − − +
C2 103 M 3
No protein 
deposit+vascular 
disease
− − − +
C3 81 F 3.3 PART (Braak I)+vascular disase − − − +
C4 61 M 8 PART (Braak I) −  − + −
Low AD
I1 88 M 1 3.45 AD (A2B1C2) ++ + ++ ++
I2 85 F 8 2 AD (A2B1C1) − − + +
I3 80 M 5 3 AD (A2B1C1) ++ ++ ++ +++ 
I4 75 F n.d 6 AD (A1B1C1) −  − + +
I5 72 F n.d 4 AD (A1B1C1) −  − + +
intermediate 
AD
M1 85 M 12 3.3 AD (A2B2C2) − + +++    +++ 
M2 97 F 9 n.d AD (A2B2C2) n.d n.d n.d n.d
M3 77 M 17 1.5 AD (A2B2C1) − − ++  ++
M4 86 F 9 3 AD (A2B2C2) − + ++  ++
High AD
A1 77 F 16 4 AD (A2B3C3) + +++ +++    +++ 
A2 70 M 4 2.5 AD (A3B3C3) ++ +++ ++    +++ 
A3 89 M 13 3 AD (A2B3C3) + +++ +++    +++ 
A4 86 M 8 2.5 AD (A3B3C3) + − +  ++
A5 93 M 3 2.4 AD (A3B3C3) + +++ +++    +++ 
The neuropathological assessment was performed according to Thal phases, adapted CERAD score, NIA-AA guidelines and 
PART criteria. Aβ immunopositivity was scored on a 4-tiered scale as: (−) negative, (+) 1–2isolated Aβ depositions, (++) 
3–4Aβ depositions, and (+++) >4 Aβ depositions. Graduation of phospho-TAU deposit: (−) negative +: low; ++: intermediate; 
+++ high. PMI: post-mortem interval; n.d: not determined; MP: Mature plaques; DP: Diffuse plaques.
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of most APP and Tau interactors mentioned in this study 
in a spatial and stage-dependent manner across AD brains.
Although the analysis of the OB transcriptome 
provides a unique window into their biochemistry 
and dysfunction across AD stages, there are potential 
limitations of our study that warrant discussion. We 
have processed all cellular layers present in the bulk 
OB, giving novel insight into the gene-expression in 
this olfactory area. However, the OB is composed by 
intermixed multiple cell types with intricate architecture 
and connectivity [31], and information about specific-cell 
types where mRNAs originated from is lost in our dataset. 
The implementation of novel workflows that allow the 
exploration of olfactory cell-type specific transcriptomes 
[32] would complement the output of our nonbiased 
profiling of the OB transcriptome, minimizing the effect of 
multiple neuronal microenvironments, and deciphering the 
specific role of each olfactory neuronal population during 
AD progression.
Progressive modulation of olfactory pathways 
across AD staging
To obtain a functional genomic perspective, 
differential transcriptomes were analyzed for higher-level 
organization of genes into common biological pathways 
using the Reactome database [33] (Supplementary Table 5). 
As shown in Figure 4, our results point out a stage-
dependent deregulation of specific pathways. Gene clusters 
involved in hemostasis, metabolism of carbohydrates, and 
metabolism of proteins were mapped across AD stages 
(Figure 4A), confirming previous observations obtained at 
protein level using proteomic workflows [34]. Moreover, 
a de-regulation of genes involved in signal transduction, 
immune system, and molecular transport was also 
evidenced across AD staging (Figure 4A), reinforcing 
the idea that cellular signaling and neuroinflammation 
are common driving forces of AD pathology across brain 
structures [12]. Gastrin-CREB signaling is involved in 
neurogenesis and cognitive impairment at hippocampal 
level [35], suggesting that the slight alteration in this 
pathway in initial-intermediate stages (Figure 4B) might 
play a role in the disruption of olfactory neurogenesis that 
occur in AD [36]. In addition, OB HLA-DR genes involved 
in MHC class II presentation pathway were up-regulated 
in intermediate stages (Figure 4B), in accordance with 
previous transcriptomic experiments performed in cortical 
structures from AD patients [16, 24, 27]. In line with 
these findings, an increase in HLA-DR immunopositive 
microglia across all layers of the cortex has been detected 
in post-mortem AD brains [37]. A deregulation of sensory 
perception of smell has been proposed from transcriptomic 
information extracted from prefrontal cortex derived 
from AD subjects [16]. Accordingly, olfactory receptor 
Table 2: Common differentially expressed genes across AD staging
Gene name Gene description
LOW AD INTERMEDIATE AD HIGH AD
p-Val FC p-Val FC p-Val FC
EGFLAM EGF-like, fibronectin type III and laminin G domains 0.002 0.48 0.003 0.48 0.009 0.55
LOC391636 chromosome 9 open reading frame 78 pseudogene 0.000 0.55 0.003 0.62 0.000 0.57
RN5S344 RNA, 5S ribosomal 344 0.003 0.60 0.003 0.59 0.000 0.41
SCARNA2 small Cajal body-specific RNA 2 0.004 0.72 0.002 0.68 0.010 0.25
FLJ39739 uncharacterized FLJ39739 0.007 1.33 0.005 1.37 0.004 1.37
MRPL23-AS1 MRPL23 antisense RNA 1 (non-protein coding) 0.004 1.34 0.009 1.32 0.000 1.53
SLC39A11 solute carrier family 39 (metal ion transporter), member 11 0.002 1.54 0.001 1.70 0.000 1.98
LCN10 lipocalin 10 0.009 1.61 0.002 1.82 0.000 2.00
CCHCR1 coiled-coil alpha-helical rod protein 1 0.000 1.74 0.004 1.48 0.004 1.46
SLC5A11 solute carrier family 5 (sodium/glucose cotransporter), member 11 0.001 2.30 0.002 2.30 0.010 1.89
TMSB15B thymosin beta 15B 0.006 0.72 0.006 0.71 n.s n.s
SLIT3 slit homolog 3 (Drosophila) 0.005 1.46 0.008 1.45 n.s n.s
RNU7-76P RNA, U7 small nuclear 76 pseudogene 0.003 1.54 0.010 1.47 n.s n.s
HCRTR1 hypocretin (orexin) receptor 1 0.003 1.55 0.007 1.51 n.s n.s
TMEM186 transmembrane protein 186 0.006 1.55 0.008 1.55 n.s n.s
RAB7L1 RAB7, member RAS oncogene family-like 1 0.003 1.58 0.007 1.52 n.s n.s
SYT13 synaptotagmin XIII 0.002 1.74 0.010 1.57 n.s n.s
SNORD116-27 small nucleolar RNA, C/D box 116-27 n.s n.s 0.000 0.42 0.003 0.53
YTHDC1 YTH domain containing 1 n.s n.s 0.008 0.56 0.006 0.56
TREX2 three prime repair exonuclease 2 n.s n.s 0.002 0.59 0.002 0.60
TK2 thymidine kinase 2, mitochondrial n.s n.s 0.001 0.61 0.007 0.68
IP6K3 inositol hexakisphosphate kinase 3 n.s n.s 0.004 1.40 0.004 1.38
ESAM endothelial cell adhesion molecule n.s n.s 0.006 1.44 0.005 1.44
RRP7B ribosomal RNA processing 7 homolog B (S. cerevisiae) 0.006 0.20 n.s n.s 0.001 0.11
SNORA36B small nucleolar RNA, H/ACA box 36B 0.001 0.36 n.s n.s 0.001 0.38
ZNF45 zinc finger protein 45 0.009 0.73 n.s n.s 0.004 0.70
PPP1R13L protein phosphatase 1, regulatory subunit 13 like 0.006 1.34 n.s n.s 0.002 1.40
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(OR) gene dysregulation has been demonstrated in 
entorhinal and frontal cortex during AD progression [38]. 
In our case, we found several de-regulated OR genes 
during AD progression at the level of OB (Figure 4B). 
In particular, OR5M1, and OR2T2 genes were down-
regulated in intermediate stages, while OR2T8, and 
OR6J1 genes were over-expressed in advanced stages 
(Supplementary Table 2). These data suggest that the 
presence of neuropathological substrates at the level of 
OB triggers a minor alteration in the OR transcriptome 
across AD stages, being necessary further developments 
that enable the analysis of OR family at protein level in the 
context of AD [11, 39, 40]. Moreover, a slight deregulation 
of a subset of functional categories was observed in 
specific AD stages. As shown in Figure 4C, degradation 
of extracellular matrix, signaling by PDGF, and DAP12 
were specifically mapped in initial stages. In line with 
our observations, gene modules regulated by PDGF, and 
DAP12 (or TYROBP) are disrupted in cortical structures 
from AD subjects [16].  Specifically, TYROBP expression 
is restricted to cells involved in the innate immunity [41], 
and is one of the causal regulator of the activated immune 
system network in late-onset AD [16]. On the other hand, 
metabolism of lipids, and aminoacids together with 
TCR signaling by ZAP-70 were exclusively detected in 
intermediate stages (Figure 4C). In advanced stages, gene 
clusters related to transcription, HSF1 activation, and ER to 
Golgi transport were specifically deregulated (Figure 4C).
Figure 2: Representative immunohistochemical analysis of β-amyloid and phospho-Tau in the OB across AD stages. 
(A) Control: negative staining of β-amyloid in the anterior olfactory nucleus (AON). Low AD: mild compact deposits of β-amyloid in the 
AON. Intermediate AD: sparse neuritic plaques of β-amyloid in the AON. High AD: mild neuritic and diffuse plaques of β-amyloid in 
the AON. (B) Control: isolated neuropil threads of phospho-Tau protein in the glomerular layer of the OB. Initial AD: Moderate neuropil 
threads and tangles of phospho-Tau protein. Intermediate AD: Severe deposit of neuropil threads of phospho-Tau protein. Advanced AD: 
Severe neuropil threads and tangles of phospho-Tau protein in the AON (All images are 20×).
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Modulation of gene interactome networks in the 
OB across AD stages
To explore the cooperative action among 
differentially expressed genes, we performed gene-scale 
interaction networks merging the olfactory genes that tend 
to be de-regulated across AD staging. Using IPA software, 
a gene interactome map has been constructed for each AD 
stage (Figures 5–7). In this case, the integrative network-
based approach allowed us to: i) elucidate the biological 
function and molecular context of the deregulated genes in 
each neuropathological stage, ii) establish a framework to 
map interaction between deregulated genes and network 
modules across AD grading, and iii) to define potential 
causal regulators of the stage-dependent networks that 
may be considered as gene targets to modulate the disease 
progression at olfactory level. In initial AD stages, the 
top deregulated pathways proposed by IPA were estrogen 
biosynthesis (p-value: 7,12E-03), cAMP-mediated 
signaling (p-value: 1,02E-02), and Gi Signaling (p-value: 
1,15E-02), suggesting a central function of EGFR in the 
functional network (Figure 5). In intermediate stages, 
communication between innate and adaptive immune cells 
(p-value. 1,59E-03), and antigen presentation pathway 
(p-value: 5,02E-03) were the top deregulated pathways, 
being TGF-beta, and CREB1 potential nodes of the 
network (Figure 6). In advanced stages, the functional 
module composed by STAT3, c-Jun, and APP nodes 
appears as one of the main axis in the network (Figure 7).
Protein expression of predictive interactome 
hubs across AD grading: Focus on olfactory 
EGFR, CREB1, TGF-beta, c-Jun and STAT3
Even though changes in their expression were not 
detected in our transcriptomic workflow, the alteration 
of some of their targets may be compatible with a 
dysregulation of their functionality during AD progression 
at the level of OB. For that, subsequent experiments were 
performed in order to monitor the OB protein expression 
of these signal transducers across AD stages. Although a 
deficient EGFR signaling affects the OBs in mice, being 
necessary for olfactory learning, and discrimination 
[42–44], an increment in olfactory EGFR protein 
expression was significantly detected in initial and 
advanced AD stages (Figure 8). Interestingly, intense 
EGFR expression has been also observed in hippocampal 
and cortical neuritic plaques from patients with 
Figure 3: Differentially expressed genes in the OB across AD-related phenotypes. (A) Differential olfactory transcriptome 
distribution across AD stages. (B) Venn diagram of common and unique differential genes between AD stages. The distribution of common 
and distinct protein-coding genes in low, intermediate, and high AD stages is shown.
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pathologically confirmed AD [45], suggesting that 
abnormal EGFR signaling could contribute to cognitive 
impairment in AD [46]. CREB1 is at a central converging 
point of activated pathways during the processes of 
synaptic strengthening and memory formation, and 
targeted therapeutic strategies focusing on augmentation 
of CREB-mediated transcription might prove beneficial for 
the enhancement of both processes in initial stages of AD 
[47–49]. Disruption of these mechanisms in AD results 
in a reduction of CREB1 activation with accompanying 
memory impairment [50, 51]. At olfactory level, most of 
the well-known activity-dependent CREB target genes 
such as C-FOS, FOSB, BDNF, NR4A2, and EGR1 [50] 
were unchanged across AD stages (with the exception 
of CYR61 that was up-regulated in advanced stages) 
(Supplementary Table 2). This transcriptomic fingerprint 
might partially corroborate the unmodified activation state 
of phosphorylated CREB (Ser133) observed at olfactory 
level during AD progression (Supplementary Figure 2). 
In relation to the predictive findings observed in Figure 7, 
it has been proposed that activated STAT3 is involved 
in the responsiveness of microglia to beta amyloid 
[52], being a common inducer of astrocyte reactivity in 
AD [53]. Moreover, STAT3 has been recently proposed 
as an upstream regulator in late onset AD at cortical 
level [27]. Accordingly, we observed an increment in the 
phosphorylation state of STAT3 (Y705) in advanced AD 
stages (Figure 8). In accordance with previous studies, 
the late STAT3 activation observed in the OB suggests 
an impairment in the differentiation process of olfactory 
Figure 4: Functional metrics of the differential OB transcriptome across AD staging. Specific pathway analysis for the 
differential OB transcriptome detected in each AD stage is shown. Blue, green, and red bars correspond to functional deregulated categories 
in low, intermediate, and high AD stages respectively.
Oncotarget69671www.impactjournals.com/oncotarget
neurons in advanced stages of the disease [54]. On the 
other hand, other hubs proposed by the interaction network 
analysis such as TGF-beta and c-Jun presented unmodified 
protein levels across AD grading (Supplementary Figure 2).
Protein expression of olfactory EGFR, CREB1, 
TGF-beta, c-Jun and STAT3 across Alzheimer-
related co-pathologies 
In contrast to the common separate investigation 
of neurological diseases, targeted cross-disease studies 
comparing shared molecular relationships may give new 
insights into possible olfactory perturbations common for 
all or some neurological disorders. In order to detect novel 
molecular features shared by different Alzheimer-related 
co-pathologies at olfactory level, we have evaluated the 
OB protein expression of EGFR, CREB1, TGF-beta, c-Jun, 
and STAT3 across several AD-related diseases (n = 28 OB 
samples). We have included pathologies with common 
smell impairment like FTLD [55, 56], PSP where olfactory 
loss occurs to a lesser extent or is absent [2, 57, 58], and 
mixed dementia. Mixed dementia is a condition in which 
AD and vascular dementia occur at the same time, and 
both separate disorders often display olfactory dysfunction 
[59, 60]. As shown in Figure 9, EGFR protein levels were 
also increased in the OB derived from mixed dementia 
subjects (Figure 9A). As previously observed in AD, OB 
TGF-beta levels were unchanged across PSP, FTLD, and 
mixed dementia (Figure 9B). In contrast, OB protein 
levels of STAT3 and CREB1 were significantly increased 
only in mixed dementia, without apparent shifts in their 
activation status (Figure 9D and 9E). Differently from AD, 
olfactory c-Jun protein levels were exclusively increased 
in mixed dementia (Figure 9C). c-Jun up-regulation has 
also been reported in entorhinal cortex and hippocampus 
from AD subjects and also in AD transgenic mice [61–63]. 
Mechanistically, the c-Jun N terminal kinase (JNK)/c-Jun 
cascade exerts its influence in aberrant processes of AD 
Figure 5: High-scoring gene interactome map for early differentially expressed genes in the OB during AD progression. 
Visual representation of the relationships between differential expressed genes and functional interactors in low AD stage. Dysregulated 
genes are highlighted in red (up-regulated) and green (down-regulated). Continuous and discontinuous lines represent direct and indirect 
interactions respectively. The complete legend including main features, molecule shapes, and relationships is found at http://ingenuity.
force.com/ipa/articles/Feature_Description/Legend.
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Figure 6: High-scoring gene interactome map for OB differentially expressed genes in intermediate AD stages. Visual 
representation of the relationships between differential expressed genes and functional interactors in intermediate stages. In this case, two 
networks were merged to facilitate the global interpretation (purple lines correspond to novel functional links after merging). Dysregulated 
genes are highlighted in red (up-regulated) and green (down-regulated). Continuous and discontinuous lines represent direct and indirect 
interactions respectively. The complete legend including main features, molecule shapes, and relationships may be found at http://ingenuity.
force.com/ipa/articles/Feature_Description/Legend.
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pathogenesis such as Tau hyperphosphorylation, amyloid 
aggregation, and synaptic dysfunction in murine models 
of AD [64–66]. According to previous studies [67, 68], 
the c-Jun overexpression observed in the OB of mixed 
dementia subjects could contribute to some AD-related 
neuropathologies present in vascular dementia such as 
beta amyloid-induced neuroinflammation and vascular 
insufficiencies.
MATERIALS AND METHODS
Materials
The following antibodies and materials were used: 
anti-GAPDH (Calbiochem), anti-EGFR (Millipore), anti-
CREB, anti-phospho CREB (S133), anti-STAT3, anti-
phospho STAT3 (Y705), anti-c-Jun (Cell signaling), and 
anti-TGF-beta (Abcam). Electrophoresis reagents were 
purchased from Biorad.
Human samples
According to the Spanish Law 14/2007 of 
Biomedical Research, inform written consent form of 
the Neurological Tissue Bank of Navarra Health Service 
was obtained for research purposes from relatives of 
patients included in this study. The study was conducted 
in accordance with the Declaration of Helsinki and all 
assessments, post-mortem evaluations, and procedures 
were previously approved by the Clinical Ethics 
Committee of Navarra Health Service. Fourteen AD 
cases were distributed into different groups according 
to specific consensus diagnostic criteria [69–71]: low, 
intermediate, and high AD neuropathological changes 
Figure 7: High-scoring gene interactome map for OB differentially expressed genes in high AD stages. Visual representation 
of the relationships between differential expressed genes and functional interactors is shown. Dysregulated genes are highlighted in red 
(up-regulated) and green (down-regulated). Continuous and discontinuous lines represent direct and indirect interactions respectively. 
The complete legend including main features, molecule shapes, and relationships may be found at http://ingenuity.force.com/ipa/articles/
Feature_Description/Legend.
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(n = 4–5/group). Four cases from elderly subjects with 
no history or histological findings of any neurological 
disease were used as a control group. All human brains 
considered in this study had a post-mortem interval (PMI) 
lower than 10 hours (Table 1). Brain processing and the 
neuropathological study for protein deposits aggregates 
beta-amyloid and phospho-Tau were performed as 
previously described [34]. For the discovery phase, 
neuropathological assessment was performed according to 
standardized neuropathological scoring/grading systems, 
including Thal phases of beta-amyloid deposition, 
Braak staging of neuro fibrillary lesions, Consortium to 
Established a Registry for Alzheimer’s Disease, National 
Institute on Aging-Alzheimer’s Association (NIA-AA) 
guidelines, and primary age-related tauopathy (PART) 
criteria [69–73]. For the cross-disease analysis, different 
clinical backgrounds were considered: Progressive 
supranuclear palsy (PSP) (n = 9 cases; 4F/5M; median 
age: 74 years), frontotemporal lobar degeneration (FTLD) 
(n = 6; 3F/3M; median age: 81 years), mixed dementia 
(mix AD VD) (n = 9 cases; 4F/5M; median age: 85 years), 
and additional controls (n = 4; 1F/3M; median age: 80 
years). In these cases, neuropathological assessment was 
performed according to standardized neuropathological 
guidelines: Mackenzie criteria for FTLD pathology [74], 
NINDS-AIREN criteria for vascular dementia [75], and 
NINDS criteria for PSP [76]. 80% of the OB samples 
included in the cross-disease phase had a PMI lower than 
10 hours (Supplementary Table 1).
Microarray hybridization and data analysis
For OB mRNA extraction, the Maxwell® 16 
simplyRNA Kit (Promega) was used. The sense cDNA 
was prepared from 1 ng of total RNA and then fragmented 
and biotinylated using Affymetrix GeneChip® WT Pico 
Kit (PN902623). Labeled sense cDNA was hybridized 
to the Affymetrix Human Gene 2.0 ST chip according 
to the manufacturer protocols and using GeneChip® 
Hybridization, Wash and Stain Kit. Genechips were 
scanned with the Affymetrix GeneChip® Scanner 3000. 
For microarray data analysis, both background correction 
Figure 8: Olfactory bulb protein expression of EGFR, and STAT3 across AD staging. (A) Representative Western blot 
gels to detect olfactory EGFR across AD grading. (B) Protein expression of Total STAT3, and active STAT3 (Y705) in the OB during AD 
progression. Right panels shows histograms of band densities. Data are presented as mean ± SEM from 3 independent OB samples per 
group. *P < 0.05 vs control group.
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and normalization were done using RMA (Robust 
Multichip Average) algorithm [77]. Then, a filtering 
process was performed to eliminate low expression probe 
sets. Applying the criterion of an expression value of 16 
in at least 2 samples for each experimental condition, 
28353 probe sets were selected. R/Bioconductor was used 
for preprocessing and statistical analysis. For analysis of 
genes related to pathological changes, individuals with 
AD pathology were compared to non-demented controls. 
LIMMA (Linear Models for Microarray Data) was used to 
find out the probe sets that showed significant differential 
expression between controls and AD stages. We first used 
a threshold criteria of False Discovery Rate (FDR) < 
5% to select differentially expressed genes. As in other 
transcriptomic studies performed in AD brains [15, 78], 
we did not achieve significant results using this criteria, 
so we worked with a p-value < 0.01 (without using any 
method for multiple testing correction). Microarray 
data files were submitted to the GEO (Gene Expression 
Omnibus) database and are available under accession 
number GSE93885.
The differential expression of RNAs was 
functionally analyzed through the use of Reactome [33], 
and QIAGEN’s Ingenuity® Pathway Analysis (IPA) 
(QIAGEN Redwood City, www.qiagen.com/ingenuity), 
in order to detect and infer differentially activated/
deactivated pathways as a result of AD phenotypes. IPA 
software comprises curated information from databases of 
Figure 9: Olfactory bulb protein expression of EGFR, CREB1, TGF-beta, c-Jun and STAT3 across proteinopathies. 
OB Protein expression was documented by Western blot. (A) EGFR expression, (B) TGF-beta expression, (C) c-Jun expression, (D) STAT3/
phospho-STAT3 (Y705) expression, and (E) CREB/phospho-CREB (S133) expression, in PSP, FTLD, and mixed dementia subjects. 
Graphs represent histograms of band densities. Data are presented as mean ± SEM from: Controls (n = 4 cases), PSP (n = 9 cases), FTLD 
(n = 6 cases), and mixed dementia (mix AD VD) (n = 9 cases). *P < 0.05 vs control group; **P < 0.01 vs control group.
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experimental and predictive origin, enabling discovery of 
highly represented functions, pathways, and interactome 
networks.
Western blotting
Equal amounts of protein (10 μg) were resolved 
in 12.5% SDS-PAGE gels. OB proteins derived from 
human samples were electrophoretically transferred onto 
nitrocellulose membranes for 45 min at 120 V. Equal 
loading of the gels was assessed by Ponceau staining. 
Membranes were probed with primary antibodies at 1:1000 
dilution in 5% nonfat milk or BSA. After incubation 
with the appropriate horseradish peroxidase-conjugated 
secondary antibody (1:5000), antibody binding was 
detected by a ChemidocäMP Imaging System (Bio-Rad) 
after incubation with an enhanced chemiluminescence 
substrate (Perkin Elmer). All Band intensities were 
measured with Image Lab Software Version 5.2 (Bio-Rad) 
and normalized to GAPDH.
CONCLUSIONS
Summing up, we have performed a stage-dependent 
comprehensive analysis of differential expression of OB 
coding transcripts during AD progression. To the best of 
our knowledge, this is the first study to characterize in 
depth, potential AD-associated transcriptional changes in 
the human OB. We performed gene set enrichment analysis 
to find the most relevant pathways and gene regulatory 
networks that are progressively modulated during AD 
progression. More importantly, using a discovery platform 
combining neuropathological diagnosis, OB transcriptome 
exploration, functional interaction data, together with a 
cross-disease analysis, a divergent olfactory expression of 
specific signal transducers has been observed across AD-
related co-pathologies, serving as a foundation for new 
research areas into the role of olfactory signaling across 
different types of dementias. 
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